Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban

Abstract

Pharmacologic agents for the treatment and prevention of venous thromboembolism in the cancer patient population are limited. Currently, low-molecular-weight heparin is recommended by national consensus guidelines for this indication. Rivaroxaban, an oral factor Xa inhibitor, is Food and Drug Administration (FDA) approved for the treatment and prevention of venous thromboembolism and offers the convenience of oral fixed-dose regimens, no routine laboratory monitoring, and has few drug and dietary interactions; however, its use in patients with cancer has not been largely studied. We report 2 cases of recurrent venous thromboembolism in patients with active cancer on rivaroxaban therapy. The first case is a 64-year-old female admitted for recurrent pulmonary embolism, and the second case is a 70-year-old female admitted for recurrent deep vein thrombosis. Both patients were receiving rivaroxaban at the time of thromboembolic recurrence. These cases serve as a reminder to health-care providers that more safety and efficacy data in the cancer patient population are needed prior to using rivaroxaban for venous thromboembolism treatment.

Keywords

anticoagulation oncology

Get full access to this article

View all access options for this article.

References

Lee

Levine

. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 suppl 1):i17–i21.

Lyman

Bohlke

Khorana

; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656.

Lensing

Prandoni

Prins

. Deep-vein thrombosis. Lancet. 1999;353(9151):479–485.

Ginsberg

. Management of venous thromboembolism. N Engl J Med. 1996;335(24):1816–1828.

Kearon

Akl

Comerota

; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e419s–494s.

Rickles

Edwards

. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood. 1983;62(1):14–31.

Sack

Jr Levin

Bell

. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56(1):1–37.

Piccioli

Prandoni

Ewenstein

. Cancer and venous thromboembolism. Am Heart J. 1996;132(4):850–855.

National Comprehensive Network. Clinical Practice Guidelines in Oncology Venous Thromboembolic Disease version 2. 2013. Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.9. Accessed January 11, 2016.

10.

Varki

. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723–1729.

11.

Kearon

Akl

Ornelas

. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report [published online ahead of print January 07, 2016]. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026. Web site. http://journal.publications.chestnet.org/article.aspx?articleid=2479255. Accessed January 11, 2016.

12.

Levine

Liebman

. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807–814.

13.

EINSTEIN Investigators Bauersachs

Berkowitz

Brenner

. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.

14.

EINSTEIN Investigators Büller

Prins

Lensin

. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297.

15.

Prins

Lensing

Brighton

; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21.

16.

Vedovati

Germini

Agnelli

. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147(2):475–483.

17.

New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer. Pharmaceutical Companies of Johnson & Johnson/Janssen. Web site. www.janssen.com. 2015. Accessed January 11, 2016.

18.

Seoul National University Hospital; Korean Society of Hematology Thrombosis Working Party. Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients with Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 January 11] Available from: http://clinicaltrials.gov/show/NCT01989845 NLM Identifier: NCT01989845.

19.

Janssen Research & Development, LLC; Bayer. A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 January 11] Available from: http://clinicaltrials.gov/show/NCT02555878 NLM Identifier: NCT02555878.

20.

London Health Sciences Centre. Gwynivere Davies, London Health Sciences Centre. Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 January 11] Available from: http://clinicaltrials.gov/show/NCT01708850 NLM Identifier: NCT01708850.

21.

Rivaroxaban [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011.